ZA201508640B - Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate - Google Patents
Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioateInfo
- Publication number
- ZA201508640B ZA201508640B ZA2015/08640A ZA201508640A ZA201508640B ZA 201508640 B ZA201508640 B ZA 201508640B ZA 2015/08640 A ZA2015/08640 A ZA 2015/08640A ZA 201508640 A ZA201508640 A ZA 201508640A ZA 201508640 B ZA201508640 B ZA 201508640B
- Authority
- ZA
- South Africa
- Prior art keywords
- 9alpha
- oxoandrosta
- 6alpha
- 16alpha
- methylbutyryloxy
- Prior art date
Links
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 title 1
- -1 carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate Chemical class 0.000 title 1
- 230000004968 inflammatory condition Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1881MU2013 | 2013-05-28 | ||
| PCT/IN2014/000359 WO2014192027A1 (en) | 2013-05-28 | 2014-05-28 | Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201508640B true ZA201508640B (en) | 2017-09-27 |
Family
ID=51300796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/08640A ZA201508640B (en) | 2013-05-28 | 2015-11-24 | Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9458187B2 (enExample) |
| EP (1) | EP3004133B1 (enExample) |
| JP (1) | JP6366696B2 (enExample) |
| KR (1) | KR20160030085A (enExample) |
| CN (1) | CN105431445A (enExample) |
| AU (1) | AU2014272640B2 (enExample) |
| BR (1) | BR112015029530A8 (enExample) |
| CA (1) | CA2912400A1 (enExample) |
| EA (1) | EA027831B9 (enExample) |
| ES (1) | ES2664019T3 (enExample) |
| IL (1) | IL242658A0 (enExample) |
| MX (1) | MX2015016283A (enExample) |
| MY (1) | MY179214A (enExample) |
| PH (1) | PH12015502652A1 (enExample) |
| SG (1) | SG11201509680TA (enExample) |
| UA (1) | UA117248C2 (enExample) |
| WO (1) | WO2014192027A1 (enExample) |
| ZA (1) | ZA201508640B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458187B2 (en) | 2013-05-28 | 2016-10-04 | Sun Pharma Advanced Research Company Limited | Methods for treatment of inflammatory conditions using S-[4-(3-fleuro-3-methylbutyryloxy)but-2-ynyl]6α, 9α-difluoro-17α-(furan-2-yl) carbonyloxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate |
| JP2018503667A (ja) | 2015-01-31 | 2018-02-08 | スン プハルマ アドバンセド リサーチ カンパニー リミテド | Ｓ−［４−（３−フルオロ−３−メチルブチリルオキシ）ブタ−２−イニル］６α，９α−ジフルオロ−１７α−（フラン−２−イル）カルボニルオキシ−１１β−ヒドロキシ−１６α−メチル−３−オキソアンドロスタ−１，４−ジエン−１７β−カルボチオエートの結晶形態 |
| CN106279341A (zh) * | 2015-05-11 | 2017-01-04 | 正大天晴药业集团股份有限公司 | 一种糠酸氟替卡松的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4335121A (en) | 1980-02-15 | 1982-06-15 | Glaxo Group Limited | Androstane carbothioates |
| US7208613B2 (en) | 2002-06-20 | 2007-04-24 | Sun Pharmaceutical Industries Limited | Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| AR059216A1 (es) * | 2006-01-27 | 2008-03-19 | Sun Pharmaceutical Ind Ltd | 11b-hidroxiandrosta-4-eno-3-onas |
| US9458187B2 (en) | 2013-05-28 | 2016-10-04 | Sun Pharma Advanced Research Company Limited | Methods for treatment of inflammatory conditions using S-[4-(3-fleuro-3-methylbutyryloxy)but-2-ynyl]6α, 9α-difluoro-17α-(furan-2-yl) carbonyloxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate |
-
2014
- 2014-05-28 US US14/893,655 patent/US9458187B2/en not_active Expired - Fee Related
- 2014-05-28 WO PCT/IN2014/000359 patent/WO2014192027A1/en not_active Ceased
- 2014-05-28 EA EA201592283A patent/EA027831B9/ru not_active IP Right Cessation
- 2014-05-28 AU AU2014272640A patent/AU2014272640B2/en not_active Ceased
- 2014-05-28 EP EP14750012.8A patent/EP3004133B1/en not_active Not-in-force
- 2014-05-28 JP JP2016516309A patent/JP6366696B2/ja not_active Expired - Fee Related
- 2014-05-28 CN CN201480030607.2A patent/CN105431445A/zh active Pending
- 2014-05-28 KR KR1020157033778A patent/KR20160030085A/ko not_active Withdrawn
- 2014-05-28 SG SG11201509680TA patent/SG11201509680TA/en unknown
- 2014-05-28 ES ES14750012.8T patent/ES2664019T3/es active Active
- 2014-05-28 UA UAA201512888A patent/UA117248C2/uk unknown
- 2014-05-28 CA CA2912400A patent/CA2912400A1/en not_active Abandoned
- 2014-05-28 MY MYPI2015704326A patent/MY179214A/en unknown
- 2014-05-28 BR BR112015029530A patent/BR112015029530A8/pt not_active Application Discontinuation
- 2014-05-28 MX MX2015016283A patent/MX2015016283A/es unknown
-
2015
- 2015-11-18 IL IL242658A patent/IL242658A0/en unknown
- 2015-11-24 ZA ZA2015/08640A patent/ZA201508640B/en unknown
- 2015-11-26 PH PH12015502652A patent/PH12015502652A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201592283A1 (ru) | 2016-04-29 |
| SG11201509680TA (en) | 2015-12-30 |
| IL242658A0 (en) | 2016-02-01 |
| EP3004133A1 (en) | 2016-04-13 |
| AU2014272640B2 (en) | 2018-04-05 |
| MX2015016283A (es) | 2016-03-11 |
| PH12015502652A1 (en) | 2016-03-07 |
| BR112015029530A2 (pt) | 2017-07-25 |
| JP6366696B2 (ja) | 2018-08-01 |
| MY179214A (en) | 2020-11-02 |
| CA2912400A1 (en) | 2014-12-04 |
| BR112015029530A8 (pt) | 2019-12-17 |
| KR20160030085A (ko) | 2016-03-16 |
| ES2664019T3 (es) | 2018-04-18 |
| AU2014272640A1 (en) | 2015-11-26 |
| EA027831B1 (ru) | 2017-09-29 |
| US20160102117A1 (en) | 2016-04-14 |
| UA117248C2 (uk) | 2018-07-10 |
| JP2016520122A (ja) | 2016-07-11 |
| WO2014192027A1 (en) | 2014-12-04 |
| EP3004133B1 (en) | 2018-03-07 |
| US9458187B2 (en) | 2016-10-04 |
| CN105431445A (zh) | 2016-03-23 |
| EA027831B9 (ru) | 2017-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
| SG10201801428RA (en) | Method for increasing expression of rna-encoded proteins | |
| PL3030663T3 (pl) | Kompozycje i sposoby kontroli leptinotarsa | |
| EP3027192A4 (en) | Methods for the treatment of solid tumors | |
| HUE042218T2 (hu) | Exonátugrást elõsegítõ készítmények izomdisztrófia kezelésére | |
| PT2992908T (pt) | Método para tratamento da superfície do implante | |
| PT2948448T (pt) | Análogos de tiadiazol e o seu uso para tratamento de doenças associadas a uma deficiência de neurónios motores smn | |
| EP2968673A4 (en) | Decellulization process of tissue transports | |
| AU2014306716B2 (en) | Compositions and methods for treating celiac sprue disease | |
| AP2015008803A0 (en) | Methods for treating psoriasis using an anti-il-23antibody | |
| SG11201507352YA (en) | Methods for purifying 5-(halomethyl)furfural | |
| EP3082841A4 (en) | Methods for treating an animal | |
| GB201308466D0 (en) | Improved process for treatment of minewater | |
| ZA201507475B (en) | Method for the treatment of gas | |
| ZA201508640B (en) | Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate | |
| IL241096A0 (en) | Treatment methods | |
| PL3369435T3 (pl) | Kompozycja do leczenia choroby zapalnej stawów | |
| FR3006580B1 (fr) | Prothese pour hernie | |
| LU92721B1 (en) | Oral suspension for treating eosinophilic esophagitis | |
| LU92599B1 (en) | Oral suspension for treating eosinophilic esophagitis | |
| GB201304811D0 (en) | Novel treatment for hypertension | |
| ZA201302565B (en) | Methods for treating hyperuricemia and related diseases | |
| GB201322778D0 (en) | Method of treatment | |
| GB201314882D0 (en) | Method of treatment | |
| AU2013904595A0 (en) | Method of treating nephropathy |